21 related articles for article (PubMed ID: 38738459)
1. Clinical outcomes of etoposide and cytarabine as consolidation in elderly patients with primary CNS lymphoma.
Kim YR; Cho H; Kim SJ; Chung H; Kook HW; Jang JE; Cheong JW; Kim JS
Oncologist; 2024 Jun; 29(6):e796-e802. PubMed ID: 38581718
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma.
Yuan X; Xie Y; Xu N; Liu H; Chen P; Zhao A; Liang Y; Qian W
Haematologica; 2024 Jun; 109(6):2005-2009. PubMed ID: 38356447
[No Abstract] [Full Text] [Related]
3. Prognostic Value of CSF IL-10 at Early Assessment of Induction Chemotherapy in Primary CNS Lymphomas: A LOC Network Study.
Herzi D; Le Garff-Tavernier M; Sourdeau E; Choquet S; Soussain C; Nichelli L; Mathon B; Mokhtari K; Laurenge A; Alentorn A; Boussen I; Alcantara M; Hoang-Xuan K; Houillier C
Neurology; 2024 Jun; 102(12):e209527. PubMed ID: 38830184
[TBL] [Abstract][Full Text] [Related]
4. The role of upfront lenalidomide maintenance for primary central nervous system lymphoma following first-line methotrexate treatment: A retrospective study.
Zhang Y; Wang W; Zhao D; Chong W; Chen C; Zhang W; Zhou D
Cancer Med; 2024 May; 13(9):e7193. PubMed ID: 38738459
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; Celico C; Falautano M; Nonis A; La Rosée P; Binder M; Fabbri A; Ilariucci F; Krampera M; Roth A; Hemmaway C; Johnson PW; Linton KM; Pukrop T; Gørløv JS; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Zanni M; Krause SW; Schmoll HJ; Hertenstein B; Rummel M; Smith J; Thurner L; Cabras G; Pennese E; Ponzoni M; Deckert M; Politi LS; Finke J; Ferranti A; Cozens K; Burger E; Ielmini N; Cavalli F; Zucca E; Illerhaus G;
Leukemia; 2022 Jul; 36(7):1870-1878. PubMed ID: 35562406
[TBL] [Abstract][Full Text] [Related]
6. Primary central nervous system lymphoma.
Schaff LR; Grommes C
Blood; 2022 Sep; 140(9):971-979. PubMed ID: 34699590
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.
Houillier C; Taillandier L; Dureau S; Lamy T; Laadhari M; Chinot O; Moluçon-Chabrot C; Soubeyran P; Gressin R; Choquet S; Damaj G; Thyss A; Abraham J; Delwail V; Gyan E; Sanhes L; Cornillon J; Garidi R; Delmer A; Tanguy ML; Al Jijakli A; Morel P; Bourquard P; Moles MP; Chauchet A; Gastinne T; Constans JM; Langer A; Martin A; Moisson P; Lacomblez L; Martin-Duverneuil N; Delgadillo D; Turbiez I; Feuvret L; Cassoux N; Touitou V; Ricard D; Hoang-Xuan K; Soussain C;
J Clin Oncol; 2019 Apr; 37(10):823-833. PubMed ID: 30785830
[TBL] [Abstract][Full Text] [Related]
8. Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.
Vu K; Mannis G; Hwang J; Geng H; Rubenstein JL
Br J Haematol; 2019 Jul; 186(1):180-183. PubMed ID: 30714128
[No Abstract] [Full Text] [Related]
9. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.
Rubenstein JL; Geng H; Fraser EJ; Formaker P; Chen L; Sharma J; Killea P; Choi K; Ventura J; Kurhanewicz J; Lowell C; Hwang J; Treseler P; Sneed PK; Li J; Wang X; Chen N; Gangoiti J; Munster PN; Damato B
Blood Adv; 2018 Jul; 2(13):1595-1607. PubMed ID: 29986852
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese.
Han X; Ji Y; Ouyang M; Zhu T; Zhou D
Sci Rep; 2017 Dec; 7(1):17053. PubMed ID: 29213063
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
McCarthy PL; Holstein SA; Petrucci MT; Richardson PG; Hulin C; Tosi P; Bringhen S; Musto P; Anderson KC; Caillot D; Gay F; Moreau P; Marit G; Jung SH; Yu Z; Winograd B; Knight RD; Palumbo A; Attal M
J Clin Oncol; 2017 Oct; 35(29):3279-3289. PubMed ID: 28742454
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Thieblemont C; Tilly H; Gomes da Silva M; Casasnovas RO; Fruchart C; Morschhauser F; Haioun C; Lazarovici J; Grosicka A; Perrot A; Trotman J; Sebban C; Caballero D; Greil R; van Eygen K; Cohen AM; Gonzalez H; Bouabdallah R; Oberic L; Corront B; Choufi B; Lopez-Guillermo A; Catalano J; Van Hoof A; Briere J; Cabeçadas J; Salles G; Gaulard P; Bosly A; Coiffier B
J Clin Oncol; 2017 Aug; 35(22):2473-2481. PubMed ID: 28426350
[TBL] [Abstract][Full Text] [Related]
13. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; Krause SW; Levis A; Schmoll HJ; Cavalli F; Finke J; Reni M; Zucca E; Illerhaus G;
Lancet Haematol; 2016 May; 3(5):e217-27. PubMed ID: 27132696
[TBL] [Abstract][Full Text] [Related]
14. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.
Langner-Lemercier S; Houillier C; Soussain C; Ghesquières H; Chinot O; Taillandier L; Soubeyran P; Lamy T; Morschhauser F; Benouaich-Amiel A; Ahle G; Moles-Moreau MP; Moluçon-Chabrot C; Bourquard P; Damaj G; Jardin F; Larrieu D; Gyan E; Gressin R; Jaccard A; Choquet S; Brion A; Casasnovas O; Colin P; Reman O; Tempescul A; Marolleau JP; Fabbro M; Naudet F; Hoang-Xuan K; Houot R
Neuro Oncol; 2016 Sep; 18(9):1297-303. PubMed ID: 26951382
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K
Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235
[TBL] [Abstract][Full Text] [Related]
16. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Omuro A; Correa DD; DeAngelis LM; Moskowitz CH; Matasar MJ; Kaley TJ; Gavrilovic IT; Nolan C; Pentsova E; Grommes CC; Panageas KS; Baser RE; Faivre G; Abrey LE; Sauter CS
Blood; 2015 Feb; 125(9):1403-10. PubMed ID: 25568347
[TBL] [Abstract][Full Text] [Related]
17. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.
Morris PG; Correa DD; Yahalom J; Raizer JJ; Schiff D; Grant B; Grimm S; Lai RK; Reiner AS; Panageas K; Karimi S; Curry R; Shah G; Abrey LE; DeAngelis LM; Omuro A
J Clin Oncol; 2013 Nov; 31(31):3971-9. PubMed ID: 24101038
[TBL] [Abstract][Full Text] [Related]
18. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).
Rubenstein JL; Hsi ED; Johnson JL; Jung SH; Nakashima MO; Grant B; Cheson BD; Kaplan LD
J Clin Oncol; 2013 Sep; 31(25):3061-8. PubMed ID: 23569323
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
